Loading stock data…
$1.46-0.12 (-7.59%)
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Century Therapeutics, Inc. in the Healthcare sector is trading at $1.46 with a market capitalization of $351M. Wall Street consensus targets $4.75 (4 analysts), implying a +225.3% move over the next 12 months. The stock is currently 52% below its 52-week high of $3.04, remaining 30.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.38M↓ | -$23.68M↓ | -$20.65M↑ | -$29.36M↑ | -$34.66M |
| Net Income | -$34.55M↓ | -$21.64M↓ | -$19.17M↑ | -$34.42M↓ | -$32.54M |
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derive...